Inflectra and C. diff - a phase IV clinical study of FDA data

Summary:

C. diff is reported as a side effect among people who take Inflectra (infliximab-dyyb), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Prednisone, and have Crohn's disease.

The phase IV clinical study analyzes which people have C. diff when taking Inflectra. It is created by eHealthMe based on reports of 52,342 people who have side effects when taking Inflectra from the FDA, and is updated regularly.

What is Inflectra?

Inflectra has active ingredients of infliximab-dyyb. eHealthMe is studying from 52,370 Inflectra users. Check the latest studies of Inflectra.

What is C. diff?

C. diff is found to be associated with 1,573 drugs and 1,776 conditions by eHealthMe. Check the latest studies of C. diff.

On Apr, 06, 2026

52,342 people reported to have side effects when taking Inflectra.
Among them, 102 people (0.19%) have C. diff.

Among these 102 people:

How long have people been on Inflectra when they have C. diff? *

What is the gender of people who have C. diff when taking Inflectra? *

female: 12.5 %
male: 87.5 %

What is the age of people who have C. diff when taking Inflectra? *

What are other drugs people take besides Inflectra? *

What are other side effects people have besides C. diff? *

Weight Increased: 44 people, 43.14%
Joint Pain: 37 people, 36.27%
Fever: 35 people, 34.31%
Malaise (a feeling of general discomfort or uneasiness): 34 people, 33.33%
Anal Fissure: 27 people, 26.47%
Nausea (feeling of having an urge to vomit): 27 people, 26.47%
Drug Level Above Therapeutic: 26 people, 25.49%
Nasopharyngitis (inflammation of the nasopharynx): 26 people, 25.49%
Weight Decreased: 25 people, 24.51%
Fatigue (feeling of tiredness): 24 people, 23.53%

What are the existing conditions these people have? *

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 58 people, 56.86%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 41 people, 40.20%
Diabetes: 4 people, 3.92%
Blood Pressure Abnormal: 4 people, 3.92%
Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 2 people, 1.96%
Oedema (fluid collection in tissue): 2 people, 1.96%
Colitis (inflammation of colon): 2 people, 1.96%
Urticaria (rash of round, red welts on the skin that itch intensely): 1 person, 0.98%
Rashes (redness): 1 person, 0.98%
Pain: 1 person, 0.98%

* Approximation only. Some reports may have incomplete information.

Do you take Inflectra and have C. diff?

- Check whether C. diff is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Inflectra:

Inflectra (52,370 reports)

C. diff treatments and more:

C. diff (13,845 reports)

Browse all side effects of Inflectra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with C. diff:

C. diff (1,573 drugs)

Browse all the conditions that are associated with C. diff:

C. diff (1,776 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on infliximab-dyyb (the active ingredients of Inflectra) and Inflectra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.